Early detection Opportunity to partner with healthcare providers and clinics focused on early detection of cognitive decline, leveraging Cognivue Clarity and Thrive to expand screening programs in neurology, geriatrics, primary care, and memory clinics.

Amyloid integration Leverage the Cognivue Amyloid Risk Measure (CARM) launch to upsell cognitive risk assessment alongside biomarker-informed pathways, targeting hospitals, research centers, and dementia specialty clinics seeking integrated risk profiling.

Strategic partnerships Capitalize on or expand collaborations similar to LearningRx to reach older adult populations; pursue partnerships with brain training, senior care, and rehabilitation networks to broaden adoption and recurring device usage.

Leadership visibility Utilize leadership appointments and company milestones to position Cognivue as a growth-focused, clinically validated platform in sales narratives, supporting enterprise deals with multi-site health systems.

Market expansion Target mid-market hospitals and independent clinics seeking rapid, interpretable cognitive screening with fast results; emphasize remaining revenue potential in a $1M–$10M revenue range peers, and the scalability of two-device solution.